Morgan Stanley’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

Morgan Stanley’s Portfolio PARN Stock Details PARN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-2,000	Closed	-$1K	–	6796
2016 Q4	$1K	Sell	2,000 -2,000	-50%	-$2.38K	﹤0.01%	6507
2016 Q3	$6K	Hold	4,000	–	–	﹤0.01%	6222
2016 Q2	$7K	Buy	4,000 +2,977	+291%	+$5.47K	﹤0.01%	6171
2016 Q1	$2K	Buy	1,023 +500	+96%	+$1.38K	﹤0.01%	6448
2015 Q4	$2K	Buy	+523	New	+$1.99K	﹤0.01%	6548
2015 Q3	–	Sell	-23	Closed	–	–	7064
2015 Q2	$0	Buy	23 +1	+5%	+$4	﹤0.01%	7034
2015 Q1	$0	Hold	22	–	–	﹤0.01%	6975
2014 Q4	$0	Buy	+22	New	+$100	﹤0.01%	7007

Other funds holding PARN

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Morgan Stanley's PARN Position: Q1 2017 in Review

Morgan Stanley sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q1 2017, closing a stake of 2,000 shares — an estimated $1K sold.

Morgan Stanley first reported a position in PARN in Q4 2014 and held it in 8 quarters. The position peaked at $7K in Q2 2016. 2 funds tracked by Wall St. Rank hold PARN as of Q1 2017.

Morgan Stanley reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q1 2017 after selling out during the quarter.
Morgan Stanley sold 2,000 Parnell Pharmaceuticals Holdings Ltd shares in Q1 2017, an estimated $1K.
Morgan Stanley first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q4 2014 and held it in 8 quarters.
Morgan Stanley's Parnell Pharmaceuticals Holdings Ltd position peaked at $7K in Q2 2016.
2 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q1 2017.

Based on Morgan Stanley's 13F filing for Q1 2017, filed 12 May 2017.